---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027026"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:08:42.596283+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics shareholders reelect two directors, ratify auditor, approve say-on-pay at 2023 annual meeting

## Summary
- John Evans elected with 48.7M for, 250k against; John Maraganore with 41.6M for, 7.4M against.
- Ratification of Deloitte & Touche as auditor passed with 60.1M for, 32k against.
- Advisory vote on executive compensation approved with 47.0M for, 2.0M against.

## SEC filing metadata
- accession: 0000950170-23-027026
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017023027026/0000950170-23-027026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017023027026/beam-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027026
- JSON: https://secwatch.observer/filing/0000950170-23-027026.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027026.txt

## Key facts
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Election of Class III directors at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 1 – Each of the following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2026 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes John Evans 48,704,446 250,291 124,211 11,303,038 John Maraganore, Ph.D. 41,623,856 7,441,072 14,020 11,303,038
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023027026/0000950170-23-027026-index.htm
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes: For Against Abstentions 60,120,184 31,889 229,913
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023027026/0000950170-23-027026-index.htm
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 47,040,443 1,996,717 41,788 11,303,038
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023027026/0000950170-23-027026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.